Is Adjuvant Chemotherapy Necessary for All Patients with pT3N0 Rectal Cancer after Upfront Surgery? A Multicenter Retrospective Study [0.03%]
所有一期手术后的pT3N0期直肠癌患者都需要辅助化疗吗？一项多中心回顾性研究
Kyong-Min Kang,Ho Yung Lee,Hong-Min Ahn et al.
Kyong-Min Kang et al.
Purpose: The role of adjuvant chemotherapy (ACT) in pathologic T3N0 (pT3N0) rectal cancer, which has a favorable prognosis, remains controversial because high-risk groups for recurrence are not well defined. This study in...
A Phase Ib/II Study of Pemigatinib in Combination with Paclitaxel in Patients with Gastric Cancer with FGFs/FGFRs Alterations [0.03%]
一项评价Pemigatinib联合白蛋白结合型紫杉醇治疗FGFs/FGFRs异常胃癌患者的 Ib/II期临床试验
Minkyu Jung,Soo Hyun Park,Hyoyoung Kim et al.
Minkyu Jung et al.
Purpose: Pemigatinib is a selective inhibitor of fibroblast growth factor receptors (FGFR) 1-3 with demonstrated activity in tumors harboring FGFR2 fusions or amplifications. This phase Ib/II trial assessed the efficacy a...
Multimodal Knowledge Graph-Guided RAG-LLM for Clinical Decision Support in Pediatric Leukemia [0.03%]
多模态知识图谱引导的RAG-LLM在儿童白血病临床决策支持中的应用
Jong Keon Song,Dong Bin Youk,Hyery Kim et al.
Jong Keon Song et al.
Purpose: This study aims to develop and evaluate a multimodal, knowledge graph-guided retrieval-augmented generation (RAG) framework for clinical decision support in pediatric acute leukemia. ...
Toward Sustainable Care in HER2-Positive Metastatic Breast Cancer: Emerging Evidence for Treatment De-escalation [0.03%]
HER2阳性转移性乳腺癌治疗降级的新兴证据助力可持续医疗护理
Matilda Xinwei Lee,Soo Chin Lee
Matilda Xinwei Lee
Major advances in the management of HER2-positive (HER2+) metastatic breast cancer (MBC) have been achieved through treatment intensification with novel HER2-targeted agents and combination strategies, resulting in substantial survival gain...
Is Complete Mesocolic Excision with Central Vascular Ligation Necessary for Suspected Early-stage Right-sided Colon Cancer? [0.03%]
中央血管结扎的完全mesocolon切除术适用于疑似早期升结肠癌吗？
Mi Jeong Choi,Duck-Woo Kim,Yu Kyung Jun et al.
Mi Jeong Choi et al.
Purpose: To assess lymph node status in patients undergoing additional surgery after endoscopic resection to evaluate the need for complete mesocolic excision with central vascular ligation for clinically suspected early-...
Therapeutic Potential of Engineered Stem Cell Line with Chemokine Receptors and TRAIL/CD::UPRT in Glioblastoma Treatment [0.03%]
基因工程干细胞在胶质母细胞瘤治疗中的潜在作用：趋化因子受体和TRAIL/CD::UPRT的作用
Stephen Ahn,Soon Min Lee,Hyo-Jin Kim et al.
Stephen Ahn et al.
Purpose: Glioblastoma (GBM) is an aggressive primary brain tumor marked by a poor prognosis and limited effectiveness of current therapies, which are often accompanied by substantial recurrence rates. To address this chal...
Comparative Effectiveness of Tafasitamab Plus Lenalidomide versus Ifosfamide, Carboplatin, Etoposide-Based Chemotherapy for Relapsed/Refractory Diffuse Large B-cell Lymphoma: An External Control Arm Study [0.03%]
塔法西单抗联合来那度胺治疗复发或难治性弥漫大B细胞淋巴瘤的效果不低于异环磷酰胺、卡铂和依托泊苷等化疗药物：一种外部对照臂研究
Kyungyeon Jung,Ju Hwan Kim,Hyunjoo Lim et al.
Kyungyeon Jung et al.
Purpose: L-MIND trial has demonstrated efficacy of tafasitamab plus lenalidomide in patients with relapsed/refractory diffuse large B-cell lymphoma (r/r DLBCL). However, real-world evidence comparing tafasitamab plus lena...
Synergistic Antitumor Activity of Combination Therapy with a MET TKI Vabametkib and a Third-Generation EGFR TKI Lazertinib in MET-Amplified EGFR-Mutant NSCLC [0.03%]
MET扩增的EGFR突变型非小细胞肺癌中MET酪氨酸激酶抑制剂Vabencilimab与第三代表皮生长因子受体酪氨酸激酶抑制剂Lazertinib联合治疗的协同抗肿瘤活性研究
Dong Kwon Kim,Jin Woo Park,Hyeon Bin Cho et al.
Dong Kwon Kim et al.
Purpose: Third-generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR TKIs) improved outcomes in EGFR-mutant non-small cell lung cancer (NSCLC); however, the subsequent development of resistance empha...
Kyu-Won Jung,Mee Joo Kang,Eun Hye Park et al.
Kyu-Won Jung et al.
Purpose: This study aimed to project cancer incidence and mortality for 2026 to estimate Korea's current cancer burden. Materials and methods: ...
Cancer Statistics in Korea: Incidence, Mortality, Survival, and Prevalence in 2023 [0.03%]
2023年韩国癌症统计：发病率、死亡率、生存率和现患率
Eun Hye Park,Kyu-Won Jung,Seo Hyun Choi et al.
Eun Hye Park et al.
Purpose: The current study provides national cancer statistics and their secular trends in Korea, including incidence, mortality, survival, and prevalence in 2023, with international comparisons. ...